WO1999002676A2 - Mutants of gef proteins - Google Patents
Mutants of gef proteins Download PDFInfo
- Publication number
- WO1999002676A2 WO1999002676A2 PCT/EP1998/004752 EP9804752W WO9902676A2 WO 1999002676 A2 WO1999002676 A2 WO 1999002676A2 EP 9804752 W EP9804752 W EP 9804752W WO 9902676 A2 WO9902676 A2 WO 9902676A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cdc25
- gef
- ras
- mutants
- mutant
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 230000002378 acidificating effect Effects 0.000 claims abstract description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004474 valine Substances 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 6
- 108010014186 ras Proteins Proteins 0.000 claims description 89
- 102000016914 ras Proteins Human genes 0.000 claims description 89
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 claims description 48
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 claims description 48
- 239000013612 plasmid Substances 0.000 claims description 46
- 235000018102 proteins Nutrition 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 claims description 21
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 claims description 21
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 206010051113 Arterial restenosis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007423 screening assay Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 16
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 abstract description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 2
- 101000580040 Mus musculus Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 32
- 230000035772 mutation Effects 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000012634 fragment Substances 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229960004799 tryptophan Drugs 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 8
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 101100247319 Drosophila melanogaster Ras64B gene Proteins 0.000 description 7
- 101150019218 RAS2 gene Proteins 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 101150069072 cdc25 gene Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 101150078861 fos gene Proteins 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000008692 neointimal formation Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010065206 ras-GRF1 Proteins 0.000 description 2
- 102000012990 ras-GRF1 Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 210000001570 DN4 alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 101100120531 Homo sapiens FOS gene Proteins 0.000 description 1
- 101001037191 Homo sapiens Hyaluronan synthase 1 Proteins 0.000 description 1
- 101100248231 Homo sapiens RASGRF1 gene Proteins 0.000 description 1
- 101000713317 Homo sapiens SLC2A4 regulator Proteins 0.000 description 1
- -1 Isopropyl- Chemical group 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- RVKIPWVMZANZLI-ZFWWWQNUSA-N Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-ZFWWWQNUSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000549435 Pria Species 0.000 description 1
- 101710156978 Ras-like protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710176296 Switch 2 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108700025906 fos Genes Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 102000051887 human SLC2A4RG Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WJZNCJIOIACDBR-UONOGXRCSA-N methyl (2r)-2-(4-methylphenyl)-2-[(2s)-piperidin-2-yl]acetate Chemical compound C([C@H]1[C@H](C(=O)OC)C=2C=CC(C)=CC=2)CCCN1 WJZNCJIOIACDBR-UONOGXRCSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108010080092 ras Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000001378 ras Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to an amino acid sequence of a Guanine Nucleotide Exchange Factor (GEF) which bears such mutation(s) to enable the effect of "sequestering" the Ras-protein effector molecule in an inactive state through a nucleotide-free ras/GEF- utant complex.
- GEF Guanine Nucleotide Exchange Factor
- the invention provides a mutant of a Guanine Nucleotide Exchange Factor (GEF) in which tryptophan (W) corresponding to position 1056 of the protein called CDC25 Mm (Swiss-prot Entry P27671) is mutated to an acidic amino acid, or both tryptophan ( ) at position 1056 and serine at position 1124 are contemporaneously mutated into an acidic amino acid and valine, respectively, resulting in a protein which slows down the GDP/GTP exchange because it does not catalitically dissociates ras from the nucleotide.
- GEF Guanine Nucleotide Exchange Factor
- Another aspect of the invention concerns the gene sequence encoding said GEF- utants.
- polypeptides/proteins of the invention take part in the activation cycle of proteins of the Ras family, as said, by "sequestering" them in the form of a complex mutant GEF/nucleotide-free Ras, so blocking the signal transduction pathway in which said Ras proteins are involved; this inhibitory action of the Ras cycle has applications in research, in the treatment of pathologies related to functional alterations of the Ras protein, like proliferative disorders, and in the development of assays suitable for the identification of agents able to disrupt the ras/GEF complex.
- Ras proteins in the control of cell differentiation and cell proliferation. In their action, they act as molecular switches cycling between an active GTP -bound state and an inactive GDP -bound state, because of a transit among a series of different conformational states. Following extracellular stimuli, the inactive GDP • bound-Ras protein, releases GDP attaining a transient "emtpy" state, which afterwards binds GTP thus reaching the active state. The intrinsic GTPase activity hydrolyzes GTP bringing Ras back to the inactive state. This cycle is unidirectional because the GTPase reaction is irreversible and because the intracellular GTP concentration is about 10 times higher than GDP concentration, so that is GTP that preferentially binds the "empty" state.
- GTPase Activating Proteins stimulate intrinsic GTPase activity of Ras proteins while the GEF, "Guanine nucleotide Exchange Factors" catalyze the GDP/GTP exchange thus favouring the formation of the active Ras -GTP complex (see Fig. 1).
- the first Ras-specific exchange factor to be cloned and sequenced was the product of the CDC25 gene of Saccharomyces cerevisiae (Camoni ⁇ et al., EMBO J 5, 1986; Martegani et ai . , 1986 EMBO J 5, 2363).
- Ras-GEF Two classes of Ras-GEF have been so far identified in mammals: the pl40 encoded by CDC25 Mm (also called Ras-GRF) (Martegani et al . , 1992 EMBO J 11, 2151-57; Shou et al., 1992 Nature 358, 351-354) and mammalian Sos (Botwell et al . , 1992 Proc. Natl. Aca . Sci. USA 89, 6511-6515).
- CDC25 Mm has been the first mammalian exchange factor cloned by using functional complementation of a cdc25 yeast mutation (Martegani et al., 1992, supra ) .
- the complete cDNA encodes a 140 kDa protein expressed only in the central nervous system. Higly homologous proteins have been later identified in rat brain (Ras-GRF) (Shou et al . , 1992 supra ) and in human brain (human CDC25) (Park et ai., Gene 1994; ⁇ 093/21314). This protein contains in its C-terminal region a 240 amino acid domain structurally and functionally homologous to the catalytic region of yeast CDC25.
- Both the full length 140 kDa protein and truncated forms spanning C-terminal regions are active in yeast where they can substitute for endogenous CDC25, moreover they are efficient exchange factors in vi tro both for human p21 ras and yeast RAS2 , while they are inactive on other Ras-like proteins (ral; rap, rac etc.). Both the full length pl40 and the truncated forms are efficient activators of p21 ras in vi vo and potentially transforming.
- GEF are extremely conserved with each other and with S. cerevisiae CDC25 both from a structural and functional point of view as shown by the ability of said mammalian GEF catalytic domains to complement cdc25 mutation in S. cerevisiae.
- Ras proteins once switched to the active state in the GTP -bound form may interact via the 2 region with their target or effector. This leads to cascade activation of the "Mitogen Activated protein Kinases” (MAPK) or “Extracellular signal Regulated Kinases” (ERK) (Marshall CJ, 1995, Cell 80, 179-185; Burgering BMT and Bos JL, 1995, TIBS 20, 18-22).
- MAPK activated by dual threonine and tyrosine phosphorylation migrates in the nucleus where it can phosphorylate transcription factors inducing transcription of several genes, such as fo ⁇ . Summary of the invention
- pharmacological interventions in pathological alterations in which the ras pathway is activated, such as neoplastic growth or neointima formation following angioplastic surgery.
- CDC25 Mm has been mutated with amino acids having different chemico-physical properties: alanine (A), glutamic acid (E), phenylalanine (F), leucine (L) and lysine (K). Furthermore, also serine corresponding to residue 1124 of CDC25 Mm has been mutated, together with the above mentioned Trp mutation. The so obtained mutants have been studied in different assays, wherein either full length proteins or fragments corresponding to the catalytic domain (which in most cases are C- terminal while in other - Sos proteins - are in the central part, Fig. 2) have been used.
- Mutants have been obtained by conventional means, using site-directed mutagenesis followed by plasmid construction for the expression of mutant GEF in E. coli , in the yeast S. cerevisiae and in mammalian cells.
- a further verification of mutant functionality has been conducted in mammalian cells by means of a fos- luciferase activity assay, according to which mammalian cells have been cotransfected with a plasmid expressing a mutant GEF and a f ⁇ s-luciferase reporter plasmid whose expression is a function of ras activity. It is well- known that ras activation brings about transcriptional activation of cellular fos genes.
- the ras activation state, and the exchanger activity as well, can thus be indirectly determined by assaying the activity of the enzyme luciferase which accumulates following transcription of the luciferase gene controlled by the fos promoter.
- Overexpression of the cataytic domain of CDC25 Mm results in a significative increase of .fos-luciferase activity in a model system where hamster (CHO) or mouse (NIH3T3) fibroblasts are cotransfected with plasmids expressing
- said mutants play a sequestering role on Ras protein, bringing it in an inactive state.
- Those mutants bind Ras in a non functional way, so blocking the signal transduction pathway downstream.
- the results of competition experiments suggest that GEF mutations allow to stabilize p21 ras in its empty nucleotide-free state, i.e the WE mutant GEF causes dissociation of the Ras -GDP complex without promoting nucleotide exchange.
- ras activity finds several application in the treatment of pathologies derived from a ras hyperactivation state.
- all oncogenic p21 ras versions present point mutations in amino acids important for the binding to the guanine nucleotide that block ras in the active state (ras -GTP) or make its formation easier (Lowy DR and Willumsen BM, 1993 Ann Rev Biochem 62, 851-891).
- one ras mutation can predispose to a particular type of tumor: for instance in a cell of the lung epithelium can predispose to an adenocarcino a .
- Literature data have recently highlighted the applicability of ras antagonist molecules in pathological situations different from tumors.
- VSMC Vascular Smooth Muscle cells
- FGF FGF
- thro bin a dominant negative ras mutant display a significative reduction of proliferation induced from the same growth factors (Iran et al . , Biochem Biophy ⁇ Res Comm 202, 1252).
- the same ras mutant has been subsequently tested in vivo in a rat angioplastic model and a significative inhibition (60%) of neointima formation has been obtained 14 days after surgical operation (Indolfi et al .
- a first object of the invention relates to a GEF mutant in which the tryptophan (W) corresponding to position 1056 in the GEF protein called CDC25 Mm , is mutated to an acidic amino acid, or in which, besides the same substitution of the tryptophan, serine corresponding to position 1124 of CDC25 M is mutated to valine.
- the mutant's sequence could be extended to the whole molecule, to the catalytic domain or, more generally, to whatever part of the molecule, provided that, when tryptophan is the only amino acid mutated, a certain number of upstream and downstream amino acids with respect to mutated tryptophan are included, for a minimum of three amino acid upstream and three amino acid downstream of the mutated site, while, when both tryptophane and serine are mutated, at least the region comprising tryptophane and serine, and whichever flanking amino acid may be required to stabilize the mutant, is included, and provided that the peptide/protein is able to bind proteins of the Ras family competing with native GEF proteins, preferably in a dominant-negative manner.
- mutants amino acid sequence in a fusion protein or combined in such a way to obtain chimaeric proteins with the desired pharmacological properties. It will also be possible to chemically modify peptides in order to increase their in vivo stability and/or bioavailability.
- Another object of the invention relates to the gene sequence encoding the above described protein or peptide, in which the codon corresponding to the Trp of the catalytic domain equivalent to position 1056 in CDC25 Mm is substituted with a codon for an acidic amino acid, preferably glutamic acid, or the codons corresponding to Trp of CDC25 Mm position 1056 and to Ser of CDC25 Mm position 1124 are substituted, respectively, with a codon for an acidic amino acid, preferably glutamic acid, and a codon for valine; plasmids carrying said nucleic acid sequences are also comprised.
- the invention further provides a method for screening substances useful to selectively disrupt the ras/GEF complex.
- the in vivo assay may comprise: a) providing a cell expressing the G ⁇ F-mutants either by themselves or as fusion proteins, whereby the expression of said mutants and/or their interaction with ras results in an easily scorable phenotype, b) contacting the cell with a candidate agent, c) measuring the scorable phenotype, d) comparing the scorable phenotype in the presence of the candidate agent to that of the untreated control.
- the in vitro assay may comprise: a) providing GEF-mutants, either by themselves or as fusion proteins, whereby interaction of mutants with ras results in an easily scorable property, b) contacting the complex with a candidate agent, c) measuring the scorable property, d) comparing the scorable property in the presence of the candidate agent to that of the untreated control.
- mutants of invention or their derivatives can be used, as said, in the therapy of tumor forms, mainly due to ras activating mutations, cardiovascular diseases, such as arterial restenosis or inflammatory states.
- compositions according to the invention will contain an effective quantity of mutant, variable as a function of the delivery route, of the pathology to be treated, of general patient conditions and will be preferentially delivered by parenteral route, in particular by intramuscular or subcutaneous injection.
- the daily dosage will be affected by several factors, such as pathology severity, weight, age and sex of the patient.
- Figure 2 shows a scheme of Ras-specific exchange factor of the Sos and CDC25-like family
- Figure 3 shows an assay of activation of a ras- dependent reporter gene in mammalian fibroblsts
- Figure 4 shows a standard exchange (a and c) and dissociation (b and d) assay in vi tro on p21 ras (a and b) and RAS21 (c and d) proteins for wild type GEF protein DC25 Mm 97 g_ ⁇ 262 an( ⁇ the mutant GEF protein CDC25 Mm 975 _ 1262 W1056E, CDC25 Mm 976 _ 1262 W1056A, CDC25 Mm g76 _ 1262 W1056L, CDC25 Mm 976 _ 12 ⁇ 2 W1056F ,
- Figure 5 shows that CDC25 Mm WE is able to dissociate non-catalytically ras-bound nucleotide, i.e.; only when present in equimolar amounts compared to p21 ras or RAS2 proteins.
- Figure 6 shows inhibition of the activity of a ras-dependent reporter gene (i ⁇ os-luciferase) by mutants
- CDC25 Mm 1 _ 1262 WE as well as by double mutant CDC25 M 1 _ Data are average + standard deviation of three experiments performed on cells stimulated with PDGF, serum or nothing for 16 hours before assay.
- F_i_gure 7 shows the dimension of tumors formed in athymic nu/nu mice by 226.4.1 (transformation focus of NIH3T3 cells transfected with the k-ras gene) cells, G2.3. (226.4.1 cells cotransfected with control plasmid (pcDNA3); G2.DN.4 (226.4.1 cells transfected with mutant CDC25 Mm 1 _ 1262 WE) cells.
- Oligonucleotide assisted site-directed mutagenesis consists in hybridizing in vi tro a single strand DNA with a synthetic oligonucleotide which is complementary to the single strand DNA except for a central mismatch region.
- Trpl056 codon the CDC25 Mm 3 '-terminal region of 1238 base pairs, presenting an elevated homology with proteins of the same family, has been cloned in an expression vector called pALT ⁇ R-1 (Promega), plasmid carrying a bacteriophage replication origin (M13 and R408) and two antibiotic resistance-encoding genes.
- pALT ⁇ R-1 Promega
- M13 and R408 bacteriophage replication origin
- the other, encoding ampicillin resistance is instead inactive.
- ssDNA single strand plasmid DNA
- Mutagenesis is based on the use of two primers. One primer is able to recover the Ampicillin resistance, the other is designed with one or more mismatches necessary to introduce the desired amino acid substitution in the gene product of interest.
- After in vi tro synthesis of the second DNA helix it is transformed into an E. coli strain mutated in the DNA repair mechanism (BMH 71-18 utS) so that it can mantain in vi vo the mismatches introduced with the synthetic oligonucleotides.
- a second transformation cycle in strain JM109 allows a correct segregation of mutant and wild type plasmids ensuring a elevated proportion of plasmids with the mutated construct.
- Mutagenized genes were completely sequenced with the dideoxy chain termination method so obtaining plasmids: pALTER-CDC25 Mm g76 _ 1262 W1056E, pALTER- CDC25 Mm 976 _ 1262 W1056A, pALTER-CDC25 Mm 976 _ 1262 W1056 , pALTER-CDC25 Mm 976 _ 1262 W1056F, pALT ⁇ R-CDC25 Mm 976 _
- CDC25 Mm W1056E/S1124A and CDC25 Mm W1056E/S1124V double mutants were constructed by swapping a 0.7 kbp Ndel / EcdRl restriction fragment encompassing codon 1124 between the CDC25 Mm W ⁇ and CDC25 Mm SA (CDC25 Mm SV) encoding genes.
- Plasmid pCYM-1 (Camonis et al., 1990, Gene 86, 263-268) is a shuttle vector in which expression of the inserted gene is controlled by the SV40 promoter, which is functional both in the yeast S. cerevisiae and in higher eukaryotic ceils.
- the pCYM-1 was linearized with the restriction enzyme Ba EI ; the ends were made blunt by treating with the Kienow fragment of E. coli DNA poiymerase I and subsequently dephosporylated with alkaline phosphatase.
- the wild type and mutant CDC25 Mm fragments and linearized and dephosporylated pCYM-1 plasmid were ligated according to standard procedures.
- Plasmid pGEX2T-CDC25 Mm 97 ⁇ _ 12 ⁇ 2 was cut with Sphl and i ⁇ indlll, digestion releasing a fragment of about 440 bp spanning the Trpl056 codon.
- the plasmid was dephosphorylated with alkaline phosphatase and purified by preparative agarose gel electrophoresis .
- the i ⁇ sil-Dralll fragment spanning the mutated 1056 codon obtained by digesting the appropriate pALTERCDC25 Mm plasmid was purified by preparative agarose gel electrophoresis and subcloned in plasmid pGEM3ESCDC25 Mm (carrying codons 812-1262 of CDC25 Mm ) digested with the same restriction enzymes, so substituting the wild type fragment with the mutant one.
- the complete CDC25 Mm wild type or mutant gene was reconstructed by subcloning in the appropriate J3a ⁇ HI and Sad-cut pGEM3 ⁇ SCDC25 Mm the Ba ⁇ f ⁇ I-Sacl fragment carrying codons 1-811 of CDC25 M which has been purified by agarose gel electrophoresis.
- the wild type or mutant CDC25 Mm gene is flancked by Xbal sites.
- the Xbal fragment carrying the full length CDC25 Mm gene was purified by preparative agarose gel electrophoresis and cloned in the Xbal site present in the polylinker of the plasmid pcDNA3 ( Invitrogen) .
- plasmids were thus obtained in this way: pcDNA3-CDC25 Mm 1 _ 1262 ; pcDNA3-CDC25 Mm 1 _ 1262 W1056 ⁇ ; pcDNA3-CDC25 Mm 1 _ 1262 W1056A.
- CDC25 Mm expression is controlled by the CMV promoter (Citomegalovirus) .
- a plasmid encoding the full length CDC25 Mm W1056E/S1124V double mutant in plasmid pCDNA3 was then constructed essentially as described above.
- Mutant GEF complementation assay in S. cerevisiae cdc25 mutants
- Transformed cells were plated on minimal selective medium, with glucose as a carbon source.
- the transformant plates after an incubation at 24°C for 36 hours (permissive temperature) were shifted to restrictive temperature (36°C). In such conditions the mutant strain does not grow, while the mutant transformed with wild type CDC25 Mm gives visible colonies 48-72 hours after the shift at the restrictive temperature.
- Flasks used for yeast growth in liquid medium were incubated in a Dubnoff water bath with shacking. Growth on plates was done in humidified atmosphere incubators.
- DNA used for transfections was purified by Quiagen
- Luciferase activity of aliquots (10 ⁇ l) of cell extracts was measured with a luminometer and Relative Light Units (RLU) values so obtained were normalized to the protein content of each sample. Data were expressed as relative luciferase activity, taking as 1 the value obtained by the wild type as shown in Fig. 5.
- transfection mixes are incubated 30 min at room temperature
- HBS buffer 20 x stock Na 2 HP0 4 -2H 2 0 21 mM dextrose 120 mM
- Hepes 400 mM NBS 2x (pH 6.95) is prepared by dilution of the 20 x stock.
- E. Lysis buffer (PROMEGA) TRIS-H 3 P0 4 24 mM CDTA 2 mM DTT 2 mM Glycerol 10%
- the protocol employed is very similar for the purification of wild type and mutant CDC25 Mrn proteins as well as for the purification of p21 ras and RAS2 proteins, all as GST-fusion proteins. In the latter case
- Dissolve cell pellet in 8 ml of lysis buffer made as follows: PBS lx (NaCl 150 mM, Na 2 HP0 4 16 M, NaH ? P0 4 4 mMpH 7.3), ⁇ -mercaptoethanol 14 mM (7 mM for Ras proteins), ⁇ DTA1 mM, PMSF0.5 M, 0.5% Triton X-100.
- Thrombin buffer (TRIS-Cl 50 mM pH 7.5, NaCl 50 mM, CaCl 2 5 mM)
- the resin is centrifuged and resuspended in equal volume of Thrombin buffer containing about 10 thrombin units/mg of fusion protein bound.
- the resin is then centrifuged and the soluble fraction, containing the protein of interest, is collected. The resin is washed twice with PBSand the three soluble fractions collected are pooled.
- a further protein purification step uses an ionic exchange colu mn to eliminate thrombin residues and possible contaminating proteins.
- a Pharmacia MonoQ column with a with a 0-1M NaCl elution gradient are used; protein gets eluted at ca. 140 mM NaCl.
- protein-containing fractions are controlled by SDS-PAGE and pooled, if required are concentrated with Centripep 10 (Centricon) and dyalized over/night against 1 liter of TRIS-Cl 50 mM pH 7.5, NaCl 50 mM, glycerol 50%, ⁇ -mercaptoethanol 7 mM.
- Nitrocellulose filters are later air dried and counted in scintillation vials containing 5 ml of scintillation fluid (Ultima Gold Packard) and counted with a Prias Counter.
- the p21 ras or RAS2 protein (2.5 M) is incubated in the presence of buffer A (50 mM TRIS-HC1 pH 7.5, MgCl 2 1 mM, 10 mM NH 4 C1, 0.5 mg/ml BSA), 3 mM EDTA and 15 ⁇ M [ 3 H]GDP.
- buffer A 50 mM TRIS-HC1 pH 7.5, MgCl 2 1 mM, 10 mM NH 4 C1, 0.5 mg/ml BSA
- 3 mM EDTA 3 mM EDTA and 15 ⁇ M [ 3 H]GDP.
- Dissociation rate of the labelled complex is measured after adding a 500 fold excess unlabelled nucleotide.
- the exchange reaction is performed by incubating the p21-GDP or RAS2-GDP complex in buffer A in the presence of [ 3 H]GTP (6 ⁇ M), in the presence as required of different concentrations of CDC25 Mm . Final volume is
- mutant CDC25 Mm g7 ⁇ _ 12 ⁇ 2 W1056 ⁇ stabilizes the p21 ras protein in its empty, nucleotide-free form.
- CDC25 Mm g7 ⁇ _ ⁇ 2 W1056E has a strong dissociating activity on the Ras -GDP complex, while being unable to promote exchange.
- PDGF stimulation allows to activate ras in a CDC25 Mm -independent way, thus reaching elevated luciferase activity values, mandatory prerequisite to show by using transient transfections the presence of a dominant negative effect (Sakaue et al . , Mol Cell Biol 15, 379-388; Zippel et al . , 1996 supra) .
- CDC25 Mm W1056E protein the fos promoter is activated to levels significantly lower in comparison to cells transfected with the empty vector. These results thus indicate that the CDC25 Mm W1056E protein is able to attenuate the ras signal transduction pathway (Fig. 6).
- the double mutant CDC25 Mm W1056E/Sll24V strongly inhibits serum-stimulated expression of the Fos- luciferase promoter gene, under conditions in which the single CDC25 Mm WE mutant is less effective, indicating that the S1124V mutation reinforces the dominant negative nature of CDC25 Mm WE.
- Example 10 Biological activi ty assay: CDC25 Mm W1056E mutant induces flat reversion of ras-transformed mammalian fibroblast ⁇ .
- the plasmid carrying the mutant cDNA was stably transfected in urine NIH3T3 fibroblasts transformed with oncogenic ras and a morphological analysis of the transfected cells was performed.
- ras oncogene activation is eel transformation characterized by morphological alterations, so that a possible ras inhibition results in a regression of the transformed phenotype.
- Cells used for this purpouse have been previously transformed by insertion of genomic human DNA carrying k-ras and selected on the basis of the ability to form foci .
- Biological activi ty assay CDC25 Mm W1056E mutant induces a severe delay in growth of ras-derived xenotransplants in nude mice
- k-ras transformed NIH3T3 G2.3 226-4.1 + empty pCDNA3 G2.DN.4 226-4.1 + pCDNA3CDC25 Mm WE it is apparent that k-ras transformed cells expressing CDC25 Mm WE have a significative delay in tumor formation, since after 14 days when the average size of the tumor formed by IO 5 226-4.1 and G2.3 cells is 12 and 9 mm, respectively, no tumor can be detected. Eventually after a further 20 days, tumor starts growing also in G2.DN4 cells, possibly because of the appearance of cells whose cell cycle progression no longer requires ras activation.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU84420/98A AU8442098A (en) | 1997-07-08 | 1998-07-07 | Mutants of gef proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI97A001627 | 1997-07-08 | ||
IT97MI001627A IT1293491B1 (en) | 1997-07-08 | 1997-07-08 | MUTANTS OF GEF PROTEINS AND PLASMIDS SUITABLE FOR THEIR SYNTHESIS |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999002676A2 true WO1999002676A2 (en) | 1999-01-21 |
WO1999002676A3 WO1999002676A3 (en) | 1999-07-08 |
Family
ID=11377527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/004752 WO1999002676A2 (en) | 1997-07-08 | 1998-07-07 | Mutants of gef proteins |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8442098A (en) |
IT (1) | IT1293491B1 (en) |
WO (1) | WO1999002676A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079429A2 (en) * | 2000-03-24 | 2001-10-25 | Shanghai Biowindow Gene Development Inc. | A novel polypeptide - human guanine nucleotide exchange factor 10and the polynucleotide encoding said polypeptide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021314A1 (en) * | 1992-04-21 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Peptides having a gdp exchange factor activity, nucleic acid sequences coding for said peptides, preparation and utilization |
-
1997
- 1997-07-08 IT IT97MI001627A patent/IT1293491B1/en active IP Right Grant
-
1998
- 1998-07-07 WO PCT/EP1998/004752 patent/WO1999002676A2/en active Application Filing
- 1998-07-07 AU AU84420/98A patent/AU8442098A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021314A1 (en) * | 1992-04-21 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Peptides having a gdp exchange factor activity, nucleic acid sequences coding for said peptides, preparation and utilization |
Non-Patent Citations (3)
Title |
---|
MARTEGANI E. ET AL.: "Cloning by functional complementation of a mouse cDNA encoding a homologoue of CDC25, a Saccharomyces cerevisiae RAS activator" EMBO JOURNAL, vol. 11, no. 6, June 1992, pages 2151-2157, XP000611568 cited in the application * |
PARK W. ET AL.: "Amino acid residues in the CDC25 guanine nucleotide exchange factor critical for interaction with Ras" MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 12, December 1994, pages 8117-8122, XP002098862 * |
PARK W. ET AL.: "Identification of a dominant-negative mutation in the yeast CDC25 guanine nucleotide exchange factor for Ras" ONCOGENE, vol. 14, no. 7, 20 February 1997, pages 831-836, XP002098824 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079429A2 (en) * | 2000-03-24 | 2001-10-25 | Shanghai Biowindow Gene Development Inc. | A novel polypeptide - human guanine nucleotide exchange factor 10and the polynucleotide encoding said polypeptide |
WO2001079429A3 (en) * | 2000-03-24 | 2002-01-03 | Shanghai Biowindow Gene Dev | A novel polypeptide - human guanine nucleotide exchange factor 10and the polynucleotide encoding said polypeptide |
Also Published As
Publication number | Publication date |
---|---|
ITMI971627A1 (en) | 1999-01-08 |
ITMI971627A0 (en) | 1997-07-08 |
WO1999002676A3 (en) | 1999-07-08 |
AU8442098A (en) | 1999-02-08 |
IT1293491B1 (en) | 1999-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016237222B2 (en) | Therapeutic agent for bile duct cancer | |
US5607918A (en) | Vascular endothelial growth factor-B and DNA coding therefor | |
Farnsworth et al. | Dominant inhibitory mutations in the Mg2+-binding site of RasH prevent its activation by GTP | |
US5955366A (en) | Polynucleotides encoding cytokine suppressive anti-inflammatory drug binding proteins | |
USRE39219E1 (en) | Growth arrest homebox gene | |
US5656595A (en) | Peptides having GDP exchange factor activity, nucleic acid sequences coding for these peptides, preparation and use | |
JPH06508154A (en) | peptide | |
USRE37952E1 (en) | Grb3-3 cDNA and polypeptides | |
WO2000052173A2 (en) | Cloned human sphingosine kinase homologues | |
US5780245A (en) | Polypeptides having a serotonin receptor activity, nucleic acids coding for these polypeptides and uses | |
AU735032B2 (en) | Peptide antagonists of DP transcription factors | |
US6797501B2 (en) | Protein tyrosine phosphatase PTP20 and related products and methods | |
WO1999002676A2 (en) | Mutants of gef proteins | |
US20030109002A1 (en) | SIRP proteins and uses thereof | |
US7749758B2 (en) | Human and mammalian stem cell-derived neuron survival factors | |
US6297019B1 (en) | Recombinant polynucleotides encoding CYP7 promoter-binding factors | |
US20050064411A1 (en) | Novel gene nedl-1 | |
KR20060104263A (en) | Human protooncogene trg and protein encoded therein | |
WO2000040718A2 (en) | MUTANTS OF GNRPs AND VECTORS SUITABLE FOR THEIR EXPRESSION | |
EP1426443B1 (en) | Human bmcc1 gene | |
JPH10165189A (en) | Human mad protein and its use | |
WO2001000825A2 (en) | Human chromosome 15 and 16 bardet-biedl syndrome polynucleotides and polypeptides and methods of use | |
WO2001032699A1 (en) | Novel human udp-glucose: glycoprotein glucosyltransferase and a polynucleotide encoding the same | |
WO2001029228A1 (en) | A novel polypeptide, a human casein kinase 48 and the polynucleotide encoding the polypeptide | |
WO2002022676A1 (en) | A longevity guarantee protein and its encoding sequence and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999508179 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |